Cochrane Abstracts
Daclizumab for relapsing remitting multiple sclerosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Daclizumab for Relapsing Remitting Multiple Sclerosis." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431307/all/Daclizumab_for_relapsing_remitting_multiple_sclerosis.
Daclizumab for relapsing remitting multiple sclerosis. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431307/all/Daclizumab_for_relapsing_remitting_multiple_sclerosis. Accessed January 13, 2026.
Daclizumab for relapsing remitting multiple sclerosis. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431307/all/Daclizumab_for_relapsing_remitting_multiple_sclerosis
Daclizumab for Relapsing Remitting Multiple Sclerosis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 January 13]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431307/all/Daclizumab_for_relapsing_remitting_multiple_sclerosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Daclizumab for relapsing remitting multiple sclerosis
ID - 431307
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431307/all/Daclizumab_for_relapsing_remitting_multiple_sclerosis
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
